Business
Admittance Of Previously Issued Shares
Admittance Of Previously Issued Shares.
About this update from Iconic Labs Plc
[{"type":"text","content":"\n \n \n RNS Number : 9273H\n Iconic Labs PLC\n 27 March 2020\n \n \n \n \n \n 27th March 2020 \n \n \n Iconic Labs Plc (\"Iconic Labs\" or the \"Company\")\n \n \n Admittance Of Previously Issued Shares\n \n \n \n \n Iconic Labs Plc (LSE:ICON) (the \"Company\"), a multi-divisional new media and technology business, is pleased to provide the following update relating to the admittance of previously issued ordinary shares of £0.00001 each in the capital of the Company (\"Ordinary Shares\").\n \n The Company had originally requested the suspension of the shares because it came to the attention of the Company that, in respect of a number of Ordinary Shares issued and allotted by the Company during 2019, not all the necessary submissions had been submitted to the FCA. Following the approval and publication of the prospectus on Wednesday 25th March these submissions have now been made.\n \n Accordingly an application has been made for 1,485,777,207 Ordinary Shares to be admitted to trading on Monday 30th March 2020, conditional upon the lifting of the trading suspension and restoration of the listing of the shares.\n \n Market Abuse Regulation (MAR) Disclosure - Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.\n \n **ENDS**\n \n For further information, please visit the Company's website www.iconiclabs.co.uk or contact:\n \n \n \n \n Damon Heath\n \n \n Shard Capital Partners LLP\n \n \n Tel: +44 (0) 20 7186 9950\n \n \n \n \n \n \n \n \n \n \n \n \n This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.\n END\n \n UPDFLFEEVLIDFII\n ","length":3422,"tagName":"div"}]